红花黄色素联合依达拉奉治疗急性脑梗死临床观察

Clinical Observation on Carthamin Yellow Combined with Edaravone in Treating Acute Cerebral Infarction

目的:观察红花黄色素联合依达拉奉治疗急性脑梗死的临床疗效。方法:将80例急性脑梗死患者随机分为治疗组42例和对照组38例;在西医常规治疗基础上,对照组给予红花黄色素治疗;治疗组在对照组治疗的基础上加用依达拉奉治疗,疗程均为2周;观察治疗前后2组患者神经功能缺损程度评分变化及疗效。结果:总有效率治疗组为90.5%,对照组为65.8%,2组差异有统计学意义(P<0.05);2组治疗后神经功能缺损评分比较差异有统计学意义(P<0.05);2组均未见不良反应。结论:红花黄色素联合依达拉奉治疗急性脑梗死安全有效,可改善患者预后。

Objective： To investigate clinical effects of carthamin yellow combined with edaravone in treating acute cerebral infarction. Methods： Eighty patients were randomized into 42 cases of the treatment group and 38 cas- es of the control group; on the foundation of routine western medicine, the control group received carthamin yellow; and the treatment group edaravone, one course of the treatment was two weeks; the changes of nerve function deficits scale and clinical effects in both groups were observed before and after treating. Results： Total effective rate of the treatment group was 90.5%, higher than 65.8% of the control group, the difference had statistical meaning （P〈0.05）; the difference presented statistical meaning in nerve function deficits scale after treating （P〈0.05）, there was no side effect. Conclusion： Carthamin yellow combined with edaravone are safe and effective in treating acute cerebral infarction, which could also improve the prognosis of the patients.